<DOC>
	<DOC>NCT02805556</DOC>
	<brief_summary>A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing</brief_summary>
	<brief_title>Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Generally healthy BMI 18.032.0 kg/m2 Men sexually active with women of childbearing potential must follow instructions for contraception for the duration of treatment plus 90 days Men must refrain from sperm donation for the length of the study and for 90 days Sign informed consent Significant medical illness Tobacco use in the last 12 months Major surgery within 4 weeks of study administration Donation of blood within 4 weeks of study administration Current or recent (within 3 months of study administration) of gastrointestinal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>